tiprankstipranks
Trending News
More News >

ValiRx Terminates LOI with TheoremRx, Focuses on Prostate Cancer Asset

Story Highlights
ValiRx Terminates LOI with TheoremRx, Focuses on Prostate Cancer Asset

Don’t Miss TipRanks’ Half-Year Sale

ValiRx plc ( (GB:VAL) ) just unveiled an announcement.

ValiRx PLC announced the termination of its Letter of Intent with TheoremRx Inc, which was initially extended until May 2025. The decision was mutual after TheoremRx chose not to amend the agreement regarding the territory of Taiwan. ValiRx plans to move its VAL201 asset into a special purpose vehicle focused on prostate cancer, with intentions to extend its patent life and explore new partnerships. This strategic shift aims to strengthen ValiRx’s position in the market, despite the setback with TheoremRx, by leveraging its technical expertise and seeking new collaborations.

More about ValiRx plc

ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health. It accelerates the translation of innovative science into impactful medicines to improve patient lives. The company provides a framework for rapid translation of science into clinical development, selecting and incubating promising drug candidates and guiding them through development to become investor-ready assets. ValiRx collaborates with diverse disciplines to streamline the drug development process and outlicenses or partners lead candidates for further clinical development and commercialization. It is listed on the AIM Market of the London Stock Exchange.

YTD Price Performance: -39.10%

Average Trading Volume: 6,254,868

Technical Sentiment Signal: Buy

Current Market Cap: £1.87M

See more insights into VAL stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1